Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18399528 | 0.94 | MAPK1 (0.41) | MAPK1GLAHDAC3HDAC1HDAC2 | |
| SCHEMBL22853571 | 0.85 | ABL1 (0.34) | MAPK1GLAHDAC3HDAC1HDAC2 | |
| SCHEMBL22018240 | 0.85 | MAPK1 (0.36) | MAPK1GLAHDAC3HDAC1HDAC2 | |
| SCHEMBL19059608 | 0.81 | HDAC3 (0.40) | MAPK1GLAHDAC3HDAC1HDAC2 | |
| SCHEMBL22018416 | 0.78 | MAPK1 (0.39) | MAPK1GLAMEN1KMT2AABL1 | |
| SCHEMBL20368738 | 0.78 | TSHR (0.40) | MAPK1GLAHDAC3HDAC1HDAC2 | |
| SCHEMBL19059705 | 0.78 | TSHR (0.40) | MAPK1GLAHDAC3HDAC1HDAC2 | |
| SCHEMBL18399595 | 0.78 | TSHR (0.40) | MAPK1GLAHDAC3HDAC1HDAC2 | |
| SCHEMBL22018233 | 0.78 | MAPK1 (0.38) | MAPK1GLAMEN1KMT2AABL1 | |
| SCHEMBL22018242 | 0.76 | SMN1; SMN2 (0.39) | MAPK1MEN1KMT2ASMN1; SMN2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828290-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | INCYTE CORPORATION (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200155527-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE HOLDINGS CORPORATION | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155527-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM2, PIM1, PIM3 | MAPK1 263/4885GLA 3818/4885HDAC3 487/4885 |
| US-10828290-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | PIM2, PIM1, PIM3 | MAPK1 263/4885GLA 3818/4885HDAC3 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.